Inhibitor Therapeutics (INTI) Stock Statistics & Valuation Metrics
Total Valuation
Inhibitor Therapeutics has a market cap or net worth of $16.82M. The enterprise value is $13.44T.
- Market Cap
- $16.82M
- Enterprise Value
- $13.44T
Share Statistics
Inhibitor Therapeutics has 173,791,960 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 173,791,960
- Owned by Insiders
- 26.75%
- Owned by Institutions
- ―
Financial Efficiency
Inhibitor Therapeutics’s return on equity (ROE) is 2.55 and return on invested capital (ROIC) is -193.63%.
- Return on Equity (ROE)
- 2.55
- Return on Assets (ROA)
- -1.31
- Return on Invested Capital (ROIC)
- -193.63%
- Return on Capital Employed (ROCE)
- -1.96
- Revenue Per Employee
- 0
- Profits Per Employee
- -412.54K
- Employee Count
- 8
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Inhibitor Therapeutics is -5.08. Inhibitor Therapeutics’s PEG ratio is -1.13.
- PE Ratio
- -5.08
- PS Ratio
- 0.00
- PB Ratio
- -6.57
- Price to FCF
- -5.23
- Price to Operating Cash Flow
- -5.22
- PEG Ratio
- -1.13
Income Statement
In the last 12 months, Inhibitor Therapeutics had revenue of 0 and earned -3.30M in profits. Earnings per share was -0.02.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -3.43M
- Pretax Income
- -3.30M
- Net Income
- -3.30M
- EBITDA
- -3.43M
- Earnings Per Share (EPS)
- -0.02
Cash Flow
In the last 12 months, operating cash flow was -3.22M and capital expenditures 0, giving a free cash flow of -3.22M billion.
- Operating Cash Flow
- -3.22M
- Free Cash Flow
- -3.22M
- Free Cash Flow per Share
- -0.02
Dividends & Yields
Inhibitor Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -19.11%
- Earnings Yield
- -19.68%
Stock Price Statistics
- Beta
- 0.21
- 52-Week Price Change
- 92.00%
- 50-Day Moving Average
- 0.09
- 200-Day Moving Average
- 0.08
- Relative Strength Index (RSI)
- 54.02
- Average Volume (3m)
- 18.30K
Financial Position
Inhibitor Therapeutics as a current ratio of 3.19, with Debt / Equity ratio of -4.77%
- Current Ratio
- 3.19
- Quick Ratio
- 3.19
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.68
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Inhibitor Therapeutics has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Inhibitor Therapeutics EV to EBITDA ratio is -4.90, with an EV/FCF ratio of -5.09.
- EV to Sales
- 0.00
- EV to EBITDA
- -4.90
- EV to Free Cash Flow
- -5.09
- EV to Operating Cash Flow
- -5.09
Balance Sheet
Inhibitor Therapeutics has $515.76K in cash and marketable securities with $47.83K in debt, giving a net cash position of $467.93K billion.
- Cash & Marketable Securities
- $515.76K
- Total Debt
- $47.83K
- Net Cash
- $467.93K
- Net Cash Per Share
- $0.00
- Tangible Book Value Per Share
- -$0.01
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Inhibitor Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- 0
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 4.00%
